EMEA-002472-PIP03-22-M01 - paediatric investigation plan

Beremagene geperpavec
PIP Human

Key facts

Active substance
Beremagene geperpavec
Therapeutic area
Dermatology
Decision number
P/0249/2023
PIP number
EMEA-002472-PIP03-22-M01
Pharmaceutical form(s)
Gel
Condition(s) / indication(s)
Treatment of dystrophic epidermolysis bullosa
Route(s) of administration
Topical use
Contact for public enquiries

Krystal Biotech, Inc.
E-mail: inquiries@krystalbio.com 
Tel.:  +1 4125865830

Decision type
PM: decision on the application for modification of an agreed PIP
Decision date
Compliance check done
No

Decision

Share this page